Рак желудка обзор литературы
1. Белявская В.А., Вардосанидзе В.К., Смирнова О.Ю., Каракин Е.И., Савкин И.В., Гервас П.А., Чердынцева Н.В., Воевода М.И. Генетический статус р53 при раке желудка: соматические мутации и полиморфизм кодона 72 // Бюллетень экспериментальной биологии и медицины. 2006. № 2. С. 205–209.
2. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2006 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2008. Т. 19. № 2. (прил. 1). С. 52–90.
3. Давыдов М.И., Тер-Ованесов М.Д. Современная стратегия хирургического лечения рака желудка // Современная онкология. 2000. Т. 2, № 1. С. 4–10.
4. Заридзе Д.Г. Эпидемиология и этиология злокачественных заболеваний. Канцерогенез. М.: Научный мир. 2000. С. 26–30; 34–56.
5. Степанов И.В., Завьялова М.В., Григорьева Е.С., Букурова Ю.А., Афанасьев С.Г., Чердынцева Н.В. Клинико-морфологические и молекулярно-генетические особенности интестинального и диффузного типов карцином желудка // Сибирский онкологический журнал. 2010. № 4 (40). С. 55–66.
6. Anagnostopoulos G.K., Stefanou D., Arkoumani E., Chalkley L., Karagiannis J., Paraskeva K., Mathou N., Dellaporta E., Tsianos E., Agnantis N.J. Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study // Acta. Gastroenterol. Belg. 2007. Vol. 70. P. 285–289.
7. Bamias A.T., Bai M.C., Agnantis N.J., Michael M.C., Alamanos Y.P., Stefanaki S.V., Razi E.D., Skarlos D.V., Kappas A.M., Pavlidis N.A. Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma // Cancer Invest. 2003. Vol. 21. P. 333–340.
8. Becker K.F., Keller G., Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer // Surg. Oncol. 2000. Vol. 9. P. 5–11.
9. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., Meltzer S.J., Rodriguez-Bigas M.A., Fodde R., Ranzani G.N., Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer // Cancer Res. 1998. Vol. 58. P. 5248–5257.
10. Buffart T.E., Overmeer R.M., Steenbergen R.D., Tijssen M., van Grieken N.C., Snijders P.J., Grabsch H.I., van de Velde C.J., Carvalho B., Meijer G.A. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer // Br. J. Cancer. 2008. Vol. 99. P. 1802–1807. doi: 10.1038/ sj.bjc.6604777.
11. Buffart T.E., van Grieken N.C., Tijssen M., Coffa J., Ylstra B., Grabsch H.I., van de Velde C.J., Carvalho B., Meijer G.A. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers // Virchows Arch. 2009. Vol. 455. P. 213–223. doi: 10.1007/s00428-009-0814-y.
12. Cancer incidence in five continents. IARC Press. 1996.
13. Corso G., Pedrazzani C., Marrelli D., Pascale V., Pinto E., Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma // Arch. Surg. 2009. Vol. 144. P. 722–727. doi: 10.1001/archsurg.2009.42.
14. Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands // J. Natl. Cancer Inst. 1994. Vol. 86. P. 1600–1608.
15. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer // Nature. 1998. Vol. 392. P. 402–405.
16. Hsu P.I., Hsieh H.L., Lee J., Lin L.F., Chen H.C., Lu P.J., Hsiao M. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer // Ann. Surg. Oncol. 2009. Vol. 16. Vol. 1686–1694. doi: 10.1245/s10434-009-0428-2.
17. Iacopetta B.J., Soong R., House A.K., Hamelin R. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes // J. Pathol. 1999. Vol. 187. P. 428–432.
18. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics // Carcinogenesis. 2008. Vol. 29. P. 673–680.
19. Kim M.S., Kim S.S., Ahn C.H., Yoo N.J., Lee S.H. Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability // Hum. Pathol. 2009. Vol. 40. P. 58–64. doi: 10.1016/j.humpath.2008.06.006.
20. Kouraklis G., Katsoulis I.E., Theocharis S., Tsourouflis G., Xipolitas N., Glinavou A., Sioka C., Kostakis A. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? // Dig. Dis. Sci. 2009. Vol. 54. P. 1015–1020. doi: 10.1007/s10620-008-0464-y.
21. La Vecchia C., Negri E., Franceschi S., Gentile A. Family history and the risk of stomach and colorectal cancer // Cancer. 1992. Vol. 70. P. 50–55.
22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histoclinical classification // Acta Pathol. Microbiol. Scand. 1965. Vol. 64. P. 31–49.
23. Lazar D., Taban S., Ardeleanu C., Simionescu C., Sporea I., Cornianu M., Vernic C. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients’ survival // Rom. J. Morphol. Embryol. 2008. Vol. 49. P. 371–379.
24. Lee H.K., Lee H.S., Yang H.K. Prognostic significance of Bcl-2 and p53 expression in gastric cancer // Int. J. Colorectal. Dis. 2003. Vol. 18. P. 518–525.
25. Leung W.K., To K.F., Chu E.S., Chan M.W., Bai A.H., Ng E.K., Chan F.K., Sung J.J. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer // Br. J. Cancer. 2005. Vol. 92. P. 2190–2194.
26. Liu F., Pan K., Zhang X., Zhang Y., Zhang L., Ma J., Dong C., Shen L., Li J., Deng D., Lin D., You W. Genetic variants in cyclooxygenase-2, expression and risk of gastric cancer and its precursors in a Chinese population // Gastroenterology. 2006. Vol. 130. P. 1975–1984.
27. Liu X.P., Tsushimi K., Tsushimi M., Tsushimi M., Oga A., Kawauchi S., Furuya T., Sasaki K. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma // Pathol. Int. 2001. Vol. 51. P. 440–444.
28. Ono H., Kondo H., Gotoda T., Shirao K., Yamaguchi H., Saito D., Hosokawa K., Shimoda T., Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer // Gut. 2001. Vol. 48. P. 225–229.
29. Otsubo T., Akiyama Y., Yanagihara K., Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cellcycle arrest and apoptosis // Br. J. Cancer. 2008. Vol. 98. P. 824–831. doi: 10.1038/sj.bjc.6604193.
30. Ottini L., Falchetti M., Saieva C., De Marco M., Masala G., Zanna I., Paglierani M., Giannini G., Gulino A., Nesi G., Mariani Costantini R., Palli D. MRE11 expression is impaired in gastric cancer with microsatellite instability // Carcinogenesis. 2004. Vol. 25. P. 2337–2343.
31. Palli D., Galli M., Caporaso N.E., Cipriani F., Decarli A., Saieva C., Fraumeni J.F. Jr., Buiatti E. Family history and risk of stomach cancer in Italy // Cancer Epidemiol. Biomarkers Prev. 1994. Vol. 3. P. 15–18.
32. Sanz-Ortega J., Steinberg S.M., Moro E., Saez M., Lopez J.A., Sierra E., Sanz-Esponera J., Merino M.J. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer // Histol. Histopathol. 2000. Vol. 15. P. 455–462.
33. Scartozzi M., Galizia E., Freddari F., Berardi R., Cellerino R., Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches // Cancer Treat. Rev. 2004. Vol. 30. P. 451–459.
34. Schlemper R.J., Kato Y., Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists // J. Gastroenterol. 2001. Vol. 36. P. 445–456.
35. Shi H., Xu J.M., Hu N.Z., Xie H.J. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma // World J. Gastroenterol. 2003. Vol. 9. P. 1421–1426.
36. Simpson A.J., Caballero O.L., Pena S.D. Microsatellite instability as a tool for the classification of gastric cancer // Trends Mol. Med. 2001. Vol. 7. P. 76–80.
37. Sugai T., Habano W., Jiao Y.F., Suzuki M., Takagane A., Nakamura S. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers // Oncology. 2005. Vol. 68. P. 548–557.
38. Tahara E. Genetic pathways of two types of gastric cancer // IARC Sci. Publ. 2004. P. 327–349.
39. Toyokawa T., Yashiro M., Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma // Oncol. Rep. 2009. Vol. 21. P. 875–880.
40. Tsugawa K., Yonemura Y., Hirono Y., Fushida S., Kaji M., Miwa K., Miyazaki I., Yamamoto H. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features // Oncology. 1998. Vol. 55. P. 475–481.
41. Ushijima T., Sasako M. Focus on gastric cancer // Cancer Cell. 2004. Vol. 5. P. 121–125.
42. Vidal O., Metges J.P., Elizalde I,. Valentíni M., Volant A., Molina R., Castells A., Pera M. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer // Br. J. Surg. 2009. Vol. 96. P. 1443–1451. doi: 10.1002/bjs.6780.
43. Watson P., Lynch H.T. Extracolonic cancer in hereditary nonpolyposis colorectal cancer // Cancer. 1993. Vol. 71. P. 677–85.
44. Wynford D., Thomas J., Blaydes J. The influence of cell context on the selection pressure for p53 mutation in human cancer // Carcinogenesis. 1998. Vol. 191. P. 29–36.
45. Yu J., Cheng Y.Y., Tao Q., Lam C.N., Geng H., Tian L.W., Wong Y.P., Tong J.H., Ying J.M., Jin H., To K.F., Chan F.K., Sung J.J. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer // Gastroenterology. 2009. Vol. 136. P. 640–651. doi: 10.1053/j.gastro.2008.10.050.
46. Zhang X.L., Yang Y.S., Xu D.P., Qu J.H., Guo M.Z., Gong Y., Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer // World J. Surg. 2009. Vol. 33. P. 2112–2118. doi: 10.1007/ s00268-009-0142-z.
47. Zhao P., Liu W., Lu Y.L. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients // World J. Gastroenterol. 2005. Vol. 11. P. 5735–5738.
48. Zheng H., Takahashi H. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray // J. Clin. Pathol. 2007. Vol. 60. P. 273–277.
1. Белявская В.А., Вардосанидзе В.К., Смирнова О.Ю., Каракин Е.И., Савкин И.В., Гервас П.А., Чердынцева Н.В., Воевода М.И. Генетический статус р53 при раке желудка: соматические мутации и полиморфизм кодона 72 // Бюллетень экспериментальной биологии и медицины. 2006. № 2. С. 205–209.
2. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2006 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2008. Т. 19. № 2. (прил. 1). С. 52–90.
3. Давыдов М.И., Тер-Ованесов М.Д. Современная стратегия хирургического лечения рака желудка // Современная онкология. 2000. Т. 2, № 1. С. 4–10.
4. Заридзе Д.Г. Эпидемиология и этиология злокачественных заболеваний. Канцерогенез. М.: Научный мир. 2000. С. 26–30; 34–56.
5. Степанов И.В., Завьялова М.В., Григорьева Е.С., Букурова Ю.А., Афанасьев С.Г., Чердынцева Н.В. Клинико-морфологические и молекулярно-генетические особенности интестинального и диффузного типов карцином желудка // Сибирский онкологический журнал. 2010. № 4 (40). С. 55–66.
6. Anagnostopoulos G.K., Stefanou D., Arkoumani E., Chalkley L., Karagiannis J., Paraskeva K., Mathou N., Dellaporta E., Tsianos E., Agnantis N.J. Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study // Acta. Gastroenterol. Belg. 2007. Vol. 70. P. 285–289.
7. Bamias A.T., Bai M.C., Agnantis N.J., Michael M.C., Alamanos Y.P., Stefanaki S.V., Razi E.D., Skarlos D.V., Kappas A.M., Pavlidis N.A. Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma // Cancer Invest. 2003. Vol. 21. P. 333–340.
8. Becker K.F., Keller G., Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer // Surg. Oncol. 2000. Vol. 9. P. 5–11.
9. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., Meltzer S.J., Rodriguez-Bigas M.A., Fodde R., Ranzani G.N., Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer // Cancer Res. 1998. Vol. 58. P. 5248–5257.
10. Buffart T.E., Overmeer R.M., Steenbergen R.D., Tijssen M., van Grieken N.C., Snijders P.J., Grabsch H.I., van de Velde C.J., Carvalho B., Meijer G.A. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer // Br. J. Cancer. 2008. Vol. 99. P. 1802–1807. doi: 10.1038/ sj.bjc.6604777.
11. Buffart T.E., van Grieken N.C., Tijssen M., Coffa J., Ylstra B., Grabsch H.I., van de Velde C.J., Carvalho B., Meijer G.A. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers // Virchows Arch. 2009. Vol. 455. P. 213–223. doi: 10.1007/s00428-009-0814-y.
12. Cancer incidence in five continents. IARC Press. 1996.
13. Corso G., Pedrazzani C., Marrelli D., Pascale V., Pinto E., Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma // Arch. Surg. 2009. Vol. 144. P. 722–727. doi: 10.1001/archsurg.2009.42.
14. Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands // J. Natl. Cancer Inst. 1994. Vol. 86. P. 1600–1608.
15. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer // Nature. 1998. Vol. 392. P. 402–405.
16. Hsu P.I., Hsieh H.L., Lee J., Lin L.F., Chen H.C., Lu P.J., Hsiao M. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer // Ann. Surg. Oncol. 2009. Vol. 16. Vol. 1686–1694. doi: 10.1245/s10434-009-0428-2.
17. Iacopetta B.J., Soong R., House A.K., Hamelin R. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes // J. Pathol. 1999. Vol. 187. P. 428–432.
18. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics // Carcinogenesis. 2008. Vol. 29. P. 673–680.
19. Kim M.S., Kim S.S., Ahn C.H., Yoo N.J., Lee S.H. Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability // Hum. Pathol. 2009. Vol. 40. P. 58–64. doi: 10.1016/j.humpath.2008.06.006.
20. Kouraklis G., Katsoulis I.E., Theocharis S., Tsourouflis G., Xipolitas N., Glinavou A., Sioka C., Kostakis A. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? // Dig. Dis. Sci. 2009. Vol. 54. P. 1015–1020. doi: 10.1007/s10620-008-0464-y.
21. La Vecchia C., Negri E., Franceschi S., Gentile A. Family history and the risk of stomach and colorectal cancer // Cancer. 1992. Vol. 70. P. 50–55.
22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histoclinical classification // Acta Pathol. Microbiol. Scand. 1965. Vol. 64. P. 31–49.
23. Lazar D., Taban S., Ardeleanu C., Simionescu C., Sporea I., Cornianu M., Vernic C. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients’ survival // Rom. J. Morphol. Embryol. 2008. Vol. 49. P. 371–379.
24. Lee H.K., Lee H.S., Yang H.K. Prognostic significance of Bcl-2 and p53 expression in gastric cancer // Int. J. Colorectal. Dis. 2003. Vol. 18. P. 518–525.
25. Leung W.K., To K.F., Chu E.S., Chan M.W., Bai A.H., Ng E.K., Chan F.K., Sung J.J. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer // Br. J. Cancer. 2005. Vol. 92. P. 2190–2194.
26. Liu F., Pan K., Zhang X., Zhang Y., Zhang L., Ma J., Dong C., Shen L., Li J., Deng D., Lin D., You W. Genetic variants in cyclooxygenase-2, expression and risk of gastric cancer and its precursors in a Chinese population // Gastroenterology. 2006. Vol. 130. P. 1975–1984.
27. Liu X.P., Tsushimi K., Tsushimi M., Tsushimi M., Oga A., Kawauchi S., Furuya T., Sasaki K. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma // Pathol. Int. 2001. Vol. 51. P. 440–444.
28. Ono H., Kondo H., Gotoda T., Shirao K., Yamaguchi H., Saito D., Hosokawa K., Shimoda T., Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer // Gut. 2001. Vol. 48. P. 225–229.
29. Otsubo T., Akiyama Y., Yanagihara K., Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cellcycle arrest and apoptosis // Br. J. Cancer. 2008. Vol. 98. P. 824–831. doi: 10.1038/sj.bjc.6604193.
30. Ottini L., Falchetti M., Saieva C., De Marco M., Masala G., Zanna I., Paglierani M., Giannini G., Gulino A., Nesi G., Mariani Costantini R., Palli D. MRE11 expression is impaired in gastric cancer with microsatellite instability // Carcinogenesis. 2004. Vol. 25. P. 2337–2343.
31. Palli D., Galli M., Caporaso N.E., Cipriani F., Decarli A., Saieva C., Fraumeni J.F. Jr., Buiatti E. Family history and risk of stomach cancer in Italy // Cancer Epidemiol. Biomarkers Prev. 1994. Vol. 3. P. 15–18.
32. Sanz-Ortega J., Steinberg S.M., Moro E., Saez M., Lopez J.A., Sierra E., Sanz-Esponera J., Merino M.J. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer // Histol. Histopathol. 2000. Vol. 15. P. 455–462.
33. Scartozzi M., Galizia E., Freddari F., Berardi R., Cellerino R., Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches // Cancer Treat. Rev. 2004. Vol. 30. P. 451–459.
34. Schlemper R.J., Kato Y., Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists // J. Gastroenterol. 2001. Vol. 36. P. 445–456.
35. Shi H., Xu J.M., Hu N.Z., Xie H.J. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma // World J. Gastroenterol. 2003. Vol. 9. P. 1421–1426.
36. Simpson A.J., Caballero O.L., Pena S.D. Microsatellite instability as a tool for the classification of gastric cancer // Trends Mol. Med. 2001. Vol. 7. P. 76–80.
37. Sugai T., Habano W., Jiao Y.F., Suzuki M., Takagane A., Nakamura S. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers // Oncology. 2005. Vol. 68. P. 548–557.
38. Tahara E. Genetic pathways of two types of gastric cancer // IARC Sci. Publ. 2004. P. 327–349.
39. Toyokawa T., Yashiro M., Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma // Oncol. Rep. 2009. Vol. 21. P. 875–880.
40. Tsugawa K., Yonemura Y., Hirono Y., Fushida S., Kaji M., Miwa K., Miyazaki I., Yamamoto H. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features // Oncology. 1998. Vol. 55. P. 475–481.
41. Ushijima T., Sasako M. Focus on gastric cancer // Cancer Cell. 2004. Vol. 5. P. 121–125.
42. Vidal O., Metges J.P., Elizalde I,. Valentíni M., Volant A., Molina R., Castells A., Pera M. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer // Br. J. Surg. 2009. Vol. 96. P. 1443–1451. doi: 10.1002/bjs.6780.
43. Watson P., Lynch H.T. Extracolonic cancer in hereditary nonpolyposis colorectal cancer // Cancer. 1993. Vol. 71. P. 677–85.
44. Wynford D., Thomas J., Blaydes J. The influence of cell context on the selection pressure for p53 mutation in human cancer // Carcinogenesis. 1998. Vol. 191. P. 29–36.
45. Yu J., Cheng Y.Y., Tao Q., Lam C.N., Geng H., Tian L.W., Wong Y.P., Tong J.H., Ying J.M., Jin H., To K.F., Chan F.K., Sung J.J. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer // Gastroenterology. 2009. Vol. 136. P. 640–651. doi: 10.1053/j.gastro.2008.10.050.
46. Zhang X.L., Yang Y.S., Xu D.P., Qu J.H., Guo M.Z., Gong Y., Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer // World J. Surg. 2009. Vol. 33. P. 2112–2118. doi: 10.1007/ s00268-009-0142-z.
47. Zhao P., Liu W., Lu Y.L. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients // World J. Gastroenterol. 2005. Vol. 11. P. 5735–5738.
48. Zheng H., Takahashi H. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray // J. Clin. Pathol. 2007. Vol. 60. P. 273–277.
Source: www.siboncoj.ru
1. Колобаев И.В. Выбор объема лимфаденэктомии при раннем раке желудка. [дис. … канд. мед. наук]. [Москва]; 2009. 105. 2. Туркин И.Н., Давыдов М.И. Что определяет объем лимфодиссекции при раннем раке желудка? Сибирский онкологический журнал. 2013; 2: 12–17. 3. Скоропад В.Ю., Бердов Б.А. Ранний (pT1) рак желудка: клиникоморфологические характеристики и результаты хирургического лечения. Анналы хирургии. 2003; 4: 30–36. 4. Lambert R. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest. Endosc. 2003; 58 (6 Suppl): S3–43.
5. Hatta W., Gotoda T., Oyama T., Kawata N., Takahashi A., Yoshifuku Y., Hoteya S., Nakagawa M., Hirano M., Esaki M., Matsuda M., Ohnita K., Yamanouchi K., Yoshida M., Dohi O., Takada J., Tanaka K., Yamada S., Tsuji T., Ito H., Hayashi Y., Nakaya N., Nakamura T., Shimosegawa T. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system”. Am J Gastroenterol. 2017 Jun; 112 (6): 874–881. doi: 10.1038/ajg.2017.95. 6. Gotoda T., Yanagisawa A., Sasako M., Ono H., Nakanishi Y., Shimoda T., Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000 Dec; 3 (4): 219–225. 7. Isozaki H., Okajima K., Ichiinona T., Fujii K., Nomura E., Izumi N., Ohyama T. Distant lymph node metastasis of early gastric cancer. Surg. Today. 1997; 27 (7): 600–605. . Abe S., Oda I., Nakajima T., Suzuki H., Nonaka S., Yoshinaga S., Sekine S., Taniguchi H., Kushima R., Iwasa S., Saito Y., Katai H. A case of local recurrence and distant metastasis following curative endoscopic submucosal dissection of early gastric cancer. Gastric Cancer. 2015; 18 (1): 188–192. doi: 10.1007/s10120-014-0341-7. 9. Han S., Hsu A., Wassef W.Y. An update in the endoscopic management of gastric cancer. Curr Opin Gastroenterol. 2016; 32 (6): 492–500. 10. Cesaretti M., Zarzavadjian L.E., Bian A. In vivo medical imaging technologies: new possibility in diagnosis of gastric cancer. Minerva Chir. 2016; 71 (4): 270–277. 11. Sumiyama K. Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric Cancer. 2017; 20 (S1): 20–27. doi: 10.1007/s10120-016-0659-4. 12. Murakami T., Iwanami E., Yasui A., Watanabe H., Chai S. The newest problems in the diagnosis of early stomach cancer. Rinsho Geka. 1962 May; 17: 321–30. 13. Yoshimori M. The natural history of early gastric cancer. Jpn. J. Clin. Oncol. 1989; 19 (2): 89–93. 14. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017 Jan; 20 (1): 1–19. doi: 10.1007/s10120-016-0622-4. 15. Ajani J.A., D’Amico T.A., Almhanna K., Bentrem D.J., Chao J., Das P., Denlinger C.S., Fanta P., Farjah F., Fuchs C.S., Gerdes H., Gibson M., Glasgow R.E., Hayman J.A., Hochwald S., Hofstetter W.L., Ilson D.H., Jaroszewski D., Johung K.L., Keswani R.N., Kleinberg L.R., Korn W.M., Leong S., Linn C., Lockhart A.C., Ly Q.P., Mulcahy M.F., Orringer M.B., Perry K.A., Poultsides G.A., Scott W.J., Strong V.E., Washington M.K., Weksler B., Willett C.G., Wright C.D., Zelman D., McMillian N., Sundar H. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016; 14 (10): 1286–1312. 16. Tanabe S., Hirabayashi S., Oda I., Ono H., Nashimoto A., Isobe Y., Nunobe S. Gastric cancer treated by endoscopic submucosal dissection or endoscopic mucosal resection in Japan from 2004 through 2006: JGCA nationwide registry conducted in 2013. Gastric Cancer. 2017 Feb 15. doi: 10.1007/s10120-017-0699-4. 17. Barreto S.G., Windsor J.A. Redefining early gastric cancer. Surg Endosc. 2016 Jan; 30 (1): 24–37. doi: 10.1007/s00464-015-4184-z. 18. Петерсон Б.Е., Чиссов В.И., Авдеев Г.И. Ранняя онкологическая патология. Медицина. 1985; 320. 19. Endoscopic Classification Review Group. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005; 37 (6): 570–578. 20. Lee J.H., Min Y.W., Lee J.H., Kim E.R., Lee H., Min B.H., Kim J.J., Jang K.T., Kim K.M., Park C.K. Diagnostic group classifications of gastric neoplasms by endoscopic resection criteria before and after treatment: real-world experience. Surg Endosc. 2016 Sep; 30 (9): 3987–93. doi: 10.1007/s00464-015-4710-z. 21. Gotoda T., Iwasaki M., Kusano C., Seewald S., Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010 Jun; 97 (6): 868–71. doi: 10.1002/bjs.7033. 22. Hasuike N., Ono H., Boku N., Mizusawa J., Takizawa K., Fukuda H., Oda I., Doyama H., Kaneko K., Hori S., Iishi H., Kurokawa Y., Muto M., Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG). A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2017 Feb 21. doi: 10.1007/s10120-017-0704-y. 23. Kim Y.H., Kim J.H., Kim H., Kim H., Lee Y.C., Lee S.K., Shin S.K., Park J.C., Chung H.S., Park J.J., Youn Y.H., Park H., Noh S.H., Choi S.H. Is the recent WHO histological classification for gastric cancer helpful for application to endoscopic resection? Gastric Cancer. 2016 Jul; 19 (3): 869–75. doi: 10.1007/s10120-015-0538-4. 24. Lee I.S., Lee S., Park Y.S., Gong C.S., Yook J.H., Kim B.S. Applicability of endoscopic submucosal dissection for undifferentiated early gastric cancer: Mixed histology of poorly differentiated adenocarcinoma and signet ring cell carcinoma is a worse predictive factor of nodal metastasis. Surg Oncol. 2017 Mar; 26 (1): 8–12. doi: 10.1016/j.suronc.2016.12.001 25. Imamura T., Komatsu S., Ichikawa D., Kawaguchi T., Kosuga T., Okamoto K., Konishi H., Shiozaki A., Fujiwara H., Otsuji E. Early signet ring cell carcinoma of the stomach is related to favorable prognosis and low incidence of lymph node metastasis. J Surg Oncol. 2016 Oct; 114 (5): 607–612. doi: 10.1002/jso.24377. 26. Tan D., Lauwers G. Gastric Cancer. Lippincott Williams & Wilkins. 2011; 348. 27. Farinati F., Rugge M., Di Mario F., Valiante F., Baffa R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.—Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy. 1993 May; 25 (4): 261–4. 28. Ryu D.G., Choi C.W., Kang D.H., Kim H.W., Park S.B., Kim S.J., Nam H.S. Clinical outcomes of endoscopic submucosa dissection for highgrade dysplasia from endoscopic forceps biopsy. Gastric Cancer. 2017 Jul; 20 (4): 671–678. doi: 10.1007/s10120-016-0665-6. 29. Fertitta A.M., Comin U., Terruzzi V., Minoli G., Zambelli A., Cannatelli G., Bodini P., Bertoli G., Negri R., Brunati S. Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy. 1993; 25 (4): 265–268. 30. Borchardt H., Borrmann R., Christeller E., Dietrich A., Fischer W., Gierke E.V., Mayer E. Verdauungsschlauch: Dritter Teil. Softcover reprint of the original 1st ed. 1929 edition. Berlin: Springer. 2012; 1076. 31. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg. 1981 Mar; 11 (2): 127–39. 32. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011 Jun; 14 (2): 101–12. doi: 10.1007/s10120-011-0041-5. 33. Ohta H., Noguchi Y., Takagi K., Nishi M., Kajitani T., Kato Y. Early gastric carcinoma with special reference to macroscopic classification. Cancer. 1987 Sep 1; 60 (5): 1099–106. 34. Ohara Y., Toshikuni N., Matsueda K., Mouri H., Yamamoto H. The superficial elevated and depressed lesion type is an independent factor associated with non-curative endoscopic submucosal dissection for early gastric cancer. Surg Endosc. 2016; 30 (11): 4880–88. 35. Abe S., Oda I., Shimazu T., Kinjo T., Tada K., Sakamoto T., Kusano C., Gotoda T. Depth-predicting score for differentiated early gastric cancer. Gastric Cancer. 2011; 14 (1): 35–40. 36. Nakamura T., Yao T., Kakeji Y., Anai H., Morita M., Oda Y., Maehara Y. Depressed type of intramucosal differentiated-type gastric cancer has high cell proliferation and reduced apoptosis compared with the elevated type. Gastric Cancer. 2013 Jan; 16 (1): 94–9. doi: 10.1007/ s10120-012-0152-7. 37. Собин Л.Х. TNM. Классификация злокачественных опухолей. Логосфера, 2011; 22. 38. Антонович В.Б. Рентгенодиагностика заболеваний пищевода, жедудка, кишечника. М.: Медицина, 1987; 400. 39. Аруин Л.И., Григорьев П.Я., Исаков В.А., Яковенко Э.П. Хронический гастрит. Амстердам, 1993; 362. 40. Park K., Jang G., Baek S., Song H. Usefulness of combined PET/ CT to assess regional lymph node involvement in gastric cancer. Tumori. 2014 Mar-Apr; 100 (2): 201–6. doi: 10.1700/1491.16415. 41. Park Y.M., Cho E., Kang H.Y., Kim J.M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011 Aug; 25 (8): 2666–77. doi: 10.1007/ s00464-011-1627-z. 42. Park J.H., Lee S.H., Park J.M., Park C.S., Park K.S., Kim E.S., Cho K.B. Prediction of the indication criteria for endoscopic resection of early gastric cancer. World J Gastroenterol. 2015 Oct 21; 21 (39): 11160–7. doi: 10.3748/wjg.v21.i39.11160. 43. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64: 31–49. 44. Chen Y.C., Fang W.L., Wang R.F., Liu C.A., Yang M.H., Lo S.S., Wu C.W., Li A.F., Shyr Y.M., Huang K.H. Clinicopathological Variation of Lauren Classification in Gastric Cancer. Pathol Oncol Res. 2016 Jan; 22 (1): 197–202. doi: 10.1007/s12253-015-9996-6. 45. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO classification of tumours of the digestive system. World Health Organization, Lyon: IARC Press, 2010; 417. 46. Lewin K.J., Appelmen H.D. Morphological variants of gastric adenocarcinoma. Tumors Esophagus Stomach. Armed Forces Inst. Pathol. Wash. DC. 1996; 313–317. 47. Everett S.M., Axon A.T.R. Early gastric cancer in Europe. Gut. 1997; 41 (2): 142–150. 48. Ming S.C. Gastric carcinoma. A pathobiological classification. Cancer. 1977; 39 (6): 2475–2485. 49. Nagayo T. Microscopical cancer of the stomach a study on histogenesis of gastric carcinoma. Int J Cancer. 1975 Jul 15; 16 (1): 52–60. 50. Grundmann E., Schlake W. Histological classification of gastric cancer from initial to advanced stages. Pathol Res Pract. 1982; 173 (3): 260–74. 51. Kodama Y., Inokuchi K., Soejima K., Matsusaka T., Okamura T. Growth patterns and prognosis in early gastric carcinoma. Superficially spreading and penetrating growth types. Cancer. 1983 Jan 15; 51 (2): 320–6. 52. Goseki N., Takizawa T., Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut. 1992 May; 33 (5): 606–12. 53. Hamilton S.R., Aaltonen L.A. WHO classification of tumours. Pathology and genetics of tumours of the digestive system. Geneva WHO, IARC Press, Lyon 2000; 103–19. 54. Fang C., Shi J., Sun Q., Gold J.S., Xu G.F., Liu W.J., Zou X.P., Huang Q. Risk factors of lymph node metastasis in early gastric carcinomas diagnosed by WHO criteria in 379 Chinese patients. J Dig Dis. 2016; 17 (8): 526–537.